SNDX

Syndax Pharmaceuticals Inc Health Care Pharmaceutical Preparations Russell 3000

$13.65Close $1.2BMarket cap $12.90 – $25.1552-week range Nov 2, 2026Next report · after the close

Highlights

Cautions

Not in an uptrend 0 of 8 trend conditions
Lagging the market RS 13 · weaker than 87% of stocks over 12 months
Far from its high 46% below its 52-week high
Distribution down-day volume 1.7× up-day volume over 50 sessions
Results soon Nov 2, 2026, in 1 day
Financial distress Altman Z″ in the distress zone

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 4, 2026

Off 12-month high 46%

1wk 1.9% price change

1mo 27.4% price change

12-month return 2% market up 11% · its own down 8%

F-score — — Not assessed

Altman Z -2.89 Elevated risk

P/E — price / earnings

PEG — P/E / EPS growth

P/B 18.5× price / book

Earnings yield 25.8% EBIT / enterprise value

Cheaper than 4% of the market · expensive

Revenue growth 628% year on year

EPS growth — latest quarter

Sales growth 92% latest quarter · -132 pts

ROE 162% return on equity

Free cash margin 188% -$323.2M FCF

D/E — long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Trade setup

ATR% 5.6% $0.76 a day · 2×ATR $12.12

RS 13 / 99 vs the universe

Trend 0 / 8 trend template

Relative volume 1.2× vs 50-day average

Up/down volume 0.60 50 sessions

Implied move — no option chain · report Nov 2, 2026

Trend template · 0 of 8

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged

Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.

Last reported Aug 4, 2026

Last shock Oct 13, 2026-16% in one session4.0× volumeno filing matched-2% since

Financials

6 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $172.4M +628% on FY2024

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$285.4M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$323.2M

Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology

Net -166%
Free cash -188%

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 87.41m +82.5% since FY2020

	FY2020Dec 31, 2020	FY2021Dec 31, 2021	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	$1.5M	$139.7M	$0	$0	$23.7M	$172.4M
Operating income	-$71.4M	$26.2M	-$151.8M	-$230.0M	-$339.7M	-$273.1M
Net income	-$73.2M	$24.9M	-$149.3M	-$209.4M	-$318.8M	-$285.4M
Net margin	-4823%	18%	—	—	-1346%	-166%
Earnings per share	-$1.77	$0.46	-$2.46	-$2.98	-$3.72	-$3.29
Free cash flow	-$71.3M	$29.0M	-$133.7M	-$160.6M	-$274.9M	-$323.2M
Free cash margin	-4697%	21%	—	—	-1161%	-188%
Cash	$115.2M	$222.0M	$74.4M	$295.4M	$154.1M	$134.9M
Long-term debt	$20.0M	$20.0M	$0	$0	$331.6M	—
Shareholders' equity	$252.2M	$408.4M	$467.4M	$554.2M	$288.1M	$64.6M
Shares outstanding	47.88m	54.98m	68.11m	84.83m	85.69m	87.41m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 4, 2026	Quarterly ↗	Jun 30, 2026	35d
Apr 30, 2026	Quarterly ↗	Mar 31, 2026	30d
Feb 26, 2026	Annual ↗	Dec 31, 2025	57d
Nov 3, 2025	Quarterly ↗	Sep 30, 2025	34d
Aug 4, 2025	Quarterly ↗	Jun 30, 2025	35d
May 5, 2025	Quarterly ↗	Mar 31, 2025	35d
Mar 3, 2025	Annual ↗	Dec 31, 2024	62d
Nov 5, 2024	Quarterly ↗	Sep 30, 2024	36d
Aug 1, 2024	Quarterly ↗	Jun 30, 2024	32d
May 8, 2024	Quarterly ↗	Mar 31, 2024	38d
Feb 27, 2024	Annual ↗	Dec 31, 2023	58d
Nov 2, 2023	Quarterly ↗	Sep 30, 2023	33d

Current reports

Filed	Disclosed
Aug 4, 2026	Results ↗
Jul 14, 2026	Other events ↗
Jun 10, 2026	Material agreement · New obligation · Unregistered share sale ↗
Jun 10, 2026	Director or officer change · Shareholder vote ↗
Jun 4, 2026	Material agreement · New obligation · Unregistered share sale · Other events ↗
Apr 30, 2026	Results ↗
Feb 26, 2026	Results ↗
Jan 12, 2026	Results · Regulation FD ↗
Dec 19, 2025	Charter or bylaws ↗
Nov 3, 2025	Results ↗
Oct 24, 2025	Other events ↗
Aug 4, 2025	Results ↗